PROTOKINETIX BLOG

Marietta, Ohio, July 20, 2022 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants. The molecule, PKX-001 (AAGP®) successfully achieved, to date, the primary...Read more

We risk skin damage every time we step into the sun, whether for work, play, or travel. The sun’s UV rays cause inflammation and sunburns, and sustained damage can lead to skin cancer, even death. And while dermatologists plead for everyone, no matter their age, color or gender, to use sunscreen, the truth is that...Read more

Advancements in medical science are making effective treatments more accessible than ever before. In its development of AAGP®, ProtoKinetix is opening the door to new cell therapies, as well as improving the efficacy of existing cell therapies. What is cell therapy? Cell therapy entails the use or transfer of human cells as a treatment for...Read more

The world over, there is increased interest in the possibility of extending human longevity. What could our lives look like if we had more control over our cells? If we had more control over disease? The potential is forever captivating. That potential is the leading driver of investment in anti-aging technology companies. As technology advances,...Read more

Marietta, Ohio, January 14, 2022- ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it will hold its Annual General Meeting of the Stockholders of the Company (“AGM”) virtually with no option to attend the AGM in person due to ongoing COVID-19 concerns. As set forth in the...Read more

Investors in ProtoKinetix, Inc., are invited to attend the annual shareholder meeting at 4 p.m. EST on Feb. 11, 2022. Join the meeting online at http://www.virtualshareholdermeeting.com/PKTX2022.

Marietta, Ohio, November 23, 2021 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP®) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation. The selection follows a...Read more

Many biotech companies have seen soaring valuations as rapid advances in biotechnology have resulted in innovative new therapies. But how can wary investors find the right companies to back — companies like ProtoKinetix (PKTX), with lean corporate management, a world-class research team, and a robust pipeline of promising research? Although biotech investing can seem like...Read more

Marietta, Ohio, May 12, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”)    (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP® (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration. The ProtoKinetix-IQVIA collaboration will aim to accelerate...Read more